103 related articles for article (PubMed ID: 25586991)
1. TRIB2 as a biomarker for diagnosis and progression of melanoma.
Hill R; Kalathur RK; Colaço L; Brandão R; Ugurel S; Futschik M; Link W
Carcinogenesis; 2015 Apr; 36(4):469-77. PubMed ID: 25586991
[TBL] [Abstract][Full Text] [Related]
2. Tribbles breaking bad: TRIB2 suppresses FOXO and acts as an oncogenic protein in melanoma.
Link W
Biochem Soc Trans; 2015 Oct; 43(5):1085-8. PubMed ID: 26517928
[TBL] [Abstract][Full Text] [Related]
3. Feasibility study on measuring selected proteins in malignant melanoma tissue by SRM quantification.
Welinder C; Jönsson G; Ingvar C; Lundgren L; Baldetorp B; Olsson H; Breslin T; Rezeli M; Jansson B; Laurell T; Fehniger TE; Wieslander E; Pawlowski K; Marko-Varga G
J Proteome Res; 2014 Mar; 13(3):1315-26. PubMed ID: 24490776
[TBL] [Abstract][Full Text] [Related]
4. Human TRIB2 is a repressor of FOXO that contributes to the malignant phenotype of melanoma cells.
Zanella F; Renner O; García B; Callejas S; Dopazo A; Peregrina S; Carnero A; Link W
Oncogene; 2010 May; 29(20):2973-82. PubMed ID: 20208562
[TBL] [Abstract][Full Text] [Related]
5. Neuropilin-2 gene expression correlates with malignant progression in cutaneous melanoma.
Rossi M; Tuck J; Kim OJ; Panova I; Symanowski JT; Mahalingam M; Riker AI; Alani RM; Ryu B
Br J Dermatol; 2014 Aug; 171(2):403-8. PubMed ID: 24359286
[TBL] [Abstract][Full Text] [Related]
6. S100 proteins as cancer biomarkers with focus on S100B in malignant melanoma.
Harpio R; Einarsson R
Clin Biochem; 2004 Jul; 37(7):512-8. PubMed ID: 15234232
[TBL] [Abstract][Full Text] [Related]
7. Melanoma biomarker expression in melanocytic tumor progression: a tissue microarray study.
Nazarian RM; Prieto VG; Elder DE; Duncan LM
J Cutan Pathol; 2010 Apr; 37 Suppl 1():41-7. PubMed ID: 20482674
[TBL] [Abstract][Full Text] [Related]
8. JWA inhibits melanoma angiogenesis by suppressing ILK signaling and is an independent prognostic biomarker for melanoma.
Lu J; Tang Y; Farshidpour M; Cheng Y; Zhang G; Jafarnejad SM; Yip A; Martinka M; Dong Z; Zhou J; Xu J; Li G
Carcinogenesis; 2013 Dec; 34(12):2778-88. PubMed ID: 24064223
[TBL] [Abstract][Full Text] [Related]
9. Osteopontin expression in plasma of melanoma patients and in melanocytic tumours.
Maier T; Laubender RP; Sturm RA; Klingenstein A; Korting HC; Ruzicka T; Berking C
J Eur Acad Dermatol Venereol; 2012 Sep; 26(9):1084-91. PubMed ID: 21838826
[TBL] [Abstract][Full Text] [Related]
10. Differential clinical significance of individual NKG2D ligands in melanoma: soluble ULBP2 as an indicator of poor prognosis superior to S100B.
Paschen A; Sucker A; Hill B; Moll I; Zapatka M; Nguyen XD; Sim GC; Gutmann I; Hassel J; Becker JC; Steinle A; Schadendorf D; Ugurel S
Clin Cancer Res; 2009 Aug; 15(16):5208-15. PubMed ID: 19671853
[TBL] [Abstract][Full Text] [Related]
11. Melanoma progression, gene expression and DNA microarrays.
Hoek KS
G Ital Dermatol Venereol; 2009 Feb; 144(1):39-49. PubMed ID: 19218910
[TBL] [Abstract][Full Text] [Related]
12. PUMA expression is significantly reduced in human cutaneous melanomas.
Karst AM; Dai DL; Martinka M; Li G
Oncogene; 2005 Feb; 24(6):1111-6. PubMed ID: 15690057
[TBL] [Abstract][Full Text] [Related]
13. Value of dopachrome tautomerase detection in the assessment of melanocytic tumors.
Filimon A; Zurac SA; Milac AL; Sima LE; Petrescu SM; Negroiu G
Melanoma Res; 2014 Jun; 24(3):219-36. PubMed ID: 24709887
[TBL] [Abstract][Full Text] [Related]
14. Molecular markers in melanoma.
Kashani-Sabet M
Br J Dermatol; 2014 Jan; 170(1):31-5. PubMed ID: 23815339
[TBL] [Abstract][Full Text] [Related]
15. Malignant melanotic schwannian tumor: a clinicopathologic, immunohistochemical, and gene expression profiling study of 40 cases, with a proposal for the reclassification of "melanotic schwannoma".
Torres-Mora J; Dry S; Li X; Binder S; Amin M; Folpe AL
Am J Surg Pathol; 2014 Jan; 38(1):94-105. PubMed ID: 24145644
[TBL] [Abstract][Full Text] [Related]
16. Gene expression profiling of primary cutaneous melanoma.
Winnepenninckx V; Van den Oord JJ
Verh K Acad Geneeskd Belg; 2007; 69(1):23-45. PubMed ID: 17427873
[TBL] [Abstract][Full Text] [Related]
17. Nuclear expression of the antiapoptotic protein survivin in malignant melanoma.
Ding Y; Prieto VG; Zhang PS; Rosenthal S; Smith KJ; Skelton HG; Diwan AH
Cancer; 2006 Mar; 106(5):1123-9. PubMed ID: 16456815
[TBL] [Abstract][Full Text] [Related]
18. Coexpression of major histocompatibility complex class II with chemokines and nuclear NFkappaB p50 in melanoma: a rational for their association with poor prognosis.
Martins I; Sylla K; Deshayes F; Lauriol J; Ghislin S; Dieu-Nosjean MC; Viguier M; Verola O; Charron D; Alcaide-Loridan C; Al-Daccak R
Melanoma Res; 2009 Aug; 19(4):226-37. PubMed ID: 19574933
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of nuclear ING3 expression in human cutaneous melanoma.
Wang Y; Dai DL; Martinka M; Li G
Clin Cancer Res; 2007 Jul; 13(14):4111-6. PubMed ID: 17634537
[TBL] [Abstract][Full Text] [Related]
20. Clinical value of combined determination of plasma L-DOPA/tyrosine ratio, S100B, MIA and LDH in melanoma.
Garnier JP; Letellier S; Cassinat B; Lebbé C; Kerob D; Baccard M; Morel P; Basset-Seguin N; Dubertret L; Bousquet B; Stoitchkov K; Le Bricon T
Eur J Cancer; 2007 Mar; 43(4):816-21. PubMed ID: 17276671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
